Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice. Aims: To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder. Method: Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10–20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score. Results: The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P < 0.0 1). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment. Conclusions: Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
WITTCHEN, H.-U., STEIN, M. B., & KESSLER, R. C. (1999) · Psychological Medicine · doi:10.1017/s0033291798008174 · Cited by 745 · cited 1×
“Social phobia or anxiety disorder is increasingly recognised as a highly prevalent and chronic disorder with onset during the teenage years (Lepine & Pelissolo, 1996;´ ´ Wittchen et al, 1999).”
Background
Cited by
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Escitalopram [430-432] 1 Clomipramine [458,459] 3”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationSheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
BackgroundAnxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Self-citationEvidence-based pharmacotherapy for personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000071 · Cited by 83
“Possibly more rapid effect of venlafaxine Kasper et al. (2005) Social phobia 358 males and females (100% generalized type) Escitalopram Began with 10 mg/d, with possible increase to 20 mg/d after 4, 6, or 8 wk for unsatisfactory response.”
BackgroundWatanabe, N., Furukawa, T. A., Chen, J., Kinoshita, Y., Nakano, Y., Ogawa, S., Funayama, T., Ietsugu, T., & Noda, Y. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-81 · Cited by 50
“In comparison with patients treated with placebo pills, several RCTs reported improvements in some QoL measures after treatment with a variety of antidepressants [15-17].”
ResultEscitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Curtiss, J., Andrews, L., Davis, M., Smits, J., & Hofmann, S. G. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285907 · Cited by 46
Nagata, T., Suzuki, F., & Teo, A. R. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12327 · Cited by 40
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
Baldwin, D. S., Asakura, S., Koyama, T., Hayano, T., Hagino, A., Reines, E., & Larsen, K. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.013 · Cited by 36
Swinson, R. P. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000601 · Cited by 17
“Since Stein and others’ review, evidence has accumulated about the efficacy of other SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs), including escitalopram (10,11), paroxetine (12,13), and venlafaxine (14).”
Anxiety Symptom Severity and Functional Recovery Or Relapse
Stein, D. J., Bandelow, B., Dolberg, O. T., Andersen, H. F., & Baldwin, D. S. (2009) · Annals of Clinical Psychiatry · doi:10.1177/104012370902100204 · Cited by 14
Self-citationRozen, N., & Aderka, I. M. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101874 · Cited by 5
Steiner, A. J., Wright, S. M., Kuhn, T., & IsHak, W. W. (2017) · Applied Research in Quality of Life · doi:10.1007/s11482-016-9485-4 · Cited by 3
Psychopharmacology for Social Anxiety Disorder
Blanco, C., Bragdon, L., Schneier, F. R., & Liebowitz, M. R. (2014) · Social Anxiety · doi:10.1016/b978-0-12-394427-6.00022-4 · Cited by 2
Metadata
- Authors
- Kasper, S., Stein, D. J., Loft, H., & Nil, R.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2005-03
- Volume
- 186
- Issue
- 3
- Pages
- 222-226
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2180149895
- Cited by
- 125
- References
- 2
- FWCI
- 20.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.